Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
BeOne Medicines Analyst Ratings and Price Targets | NASDAQ:ONC | Benzinga
BeOne Medicines Ltd has a consensus price target of $326.43 based on the ratings of 7 analysts. The high is $350 issued by Guggenheim on May 8, 2025. The low is $311 issued by RBC Capital on May 8, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Guggenheim, and RBC Capital on May 8, 2025, May 8, 2025, and April 28, 2025, respectively. With an average price target of $324.33 between RBC Capital, Guggenheim, and RBC Capital, there's an implied 31.27% upside for BeOne Medicines Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Guggenheim
TD Securities
JP Morgan
RBC Capital
1calculated from analyst ratings
Analyst Ratings for BeOne Medicines
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2025 | Buy Now | 25.87% | RBC Capital | Gregory Renza50% | $312 → $311 | Maintains | Outperform | Get Alert |
| 05/08/2025 | Buy Now | 41.65% | Guggenheim | Michael Schmidt68% | $348 → $350 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | 26.27% | RBC Capital | Gregory Renza50% | $312 → $312 | Reiterates | Outperform → Outperform | Get Alert |
| 04/24/2025 | Buy Now | 35.18% | TD Securities | Yaron Werber37% | $334 → $334 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2025 | Buy Now | 28.3% | JP Morgan | Jessica Fye67% | $311 → $317 | Maintains | Overweight | Get Alert |
| 04/16/2025 | Buy Now | — | Guggenheim | Michael Schmidt68% | — | Reiterates | Buy → Buy | Get Alert |
| 04/10/2025 | Buy Now | 40.85% | Guggenheim | Michael Schmidt68% | $348 → $348 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | 26.27% | RBC Capital | Greg Renza64% | → $312 | Initiates | → Outperform | Get Alert |
| 02/28/2025 | Buy Now | 26.68% | Macquarie | Tony Ren13% | $259 → $313 | Maintains | Outperform | Get Alert |
| 02/28/2025 | Buy Now | 40.85% | Citizens Capital Markets | Matthew Carletti84% | $288 → $348 | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for BeOne Medicines (ONC) stock?
The latest price target for BeOne Medicines (NASDAQ:ONC) was reported by RBC Capital on May 8, 2025. The analyst firm set a price target for $311.00 expecting ONC to rise to within 12 months (a possible 25.87% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BeOne Medicines (ONC)?
The latest analyst rating for BeOne Medicines (NASDAQ:ONC) was provided by RBC Capital, and BeOne Medicines maintained their outperform rating.
When was the last upgrade for BeOne Medicines (ONC)?
There is no last upgrade for BeOne Medicines
When was the last downgrade for BeOne Medicines (ONC)?
There is no last downgrade for BeOne Medicines.
When is the next analyst rating going to be posted or updated for BeOne Medicines (ONC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeOne Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeOne Medicines was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.
Is the Analyst Rating BeOne Medicines (ONC) correct?
While ratings are subjective and will change, the latest BeOne Medicines (ONC) rating was a maintained with a price target of $312.00 to $311.00. The current price BeOne Medicines (ONC) is trading at is $247.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
